Domů › Akutní myeloidní leukemie › Texas › Dallas
Klinické studie Akutní myeloidní leukemie v Dallas, TX
21 studií pro Akutní myeloidní leukemie hledá účastníky v lokalitách v Dallas a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Probíhá náborFáze 3
- Baylor University Medical Center, Dallas
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Probíhá náborFáze 1
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Probíhá náborFáze 3
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Probíhá náborFáze 1
- Children's Medical Center Dallas /ID# 275930, Dallas
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Probíhá náborFáze 3
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Probíhá náborFáze 1/2
- Baylor Scott & White Health, Dallas
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Probíhá náborFáze 3
- US-Dallas TX-SOUTHWESTERN, Dallas
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Probíhá náborFáze 1/2
- Medical City Dallas Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Probíhá náborFáze 3
- Harold C. Simmons Comprehensive Cancer Center, Dallas
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Probíhá náborFáze 3
- Texas Oncology-Presbyterian Cancer Center, Dallas
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Probíhá náborFáze 1
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Probíhá náborFáze 1
- UT Southwestern/Simmons Cancer Center, Dallas
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Probíhá náborFáze 3
- Baylor Charles A. Sammons Cancer Center, Dallas
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Probíhá náborFáze 1
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Probíhá náborObservační studie
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Probíhá náborFáze 2
- UT Southwestern Medical Center at Dallas, Dallas
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Probíhá náborFáze 1
- Baylor University Medical Center, Dallas
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Probíhá náborFáze 1
- UT Southwestern Medical Center, Dallas
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Probíhá náborFáze 2/3
- University of Texas Southwestern Medical Center, Dallas
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Probíhá náborFáze 1
- UT Southwestern - Simmons Cancer Center, Dallas
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Probíhá náborFáze 1
- University of Texas Southwestern Medical Center, Dallas
Studie Akutní myeloidní leukemie v jiných městech
- Houston, TX85 studií
- New York City, NY51 studií
- Boston, MA44 studií
- Baldwin Park, CA40 studií
- Seattle, WA40 studií
- Columbus, OH35 studií
- Philadelphia, PA34 studií
- Durham, NC33 studií
- Atlanta, GA30 studií
- Tampa, FL29 studií
- Chicago, IL26 studií
- Portland, OR25 studií
Další studie v Dallas
- Rakovina prsu55 studií
- Nemalobuněčný plicní karcinom52 studií
- Metastatický karcinom42 studií
- Srdeční selhání42 studií
- Rakovina (všechny typy)37 studií
- Rakovina prostaty36 studií
- Kolorektální karcinom33 studií
- Obesity30 studií
- Rakovina vaječníků28 studií
- Rakovina močového měchýře27 studií
- Rakovina plic27 studií
- Rakovina endometria24 studií
Zdroj: ClinicalTrials.gov, data načtena 5. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.